Quality Department, St. Charles Health System, Central Oregon, Portland, USA.
N Engl J Med. 2012 Nov 22;367(21):1998-2005. doi: 10.1056/NEJMoa1206809.
To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.
We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.
The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women--an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women--an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed.
Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. Although it is not certain which women have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.
为了降低死亡率,筛查必须在更早期、更可治愈的阶段检测出危及生命的疾病。因此,有效的癌症筛查计划既要增加早期发现的癌症发病率,又要降低晚期癌症的发病率。
我们使用监测、流行病学和最终结果数据,研究了 1976 年至 2008 年间 40 岁及以上妇女中早期乳腺癌(导管原位癌和局限性疾病)和晚期乳腺癌(区域性和远处疾病)发病率的趋势。
在美国引入筛查性乳房 X 线摄影术以来,每年检测到的早期乳腺癌病例数增加了一倍,从每 10 万名妇女 112 例增加到 234 例,每 10 万名妇女绝对增加 122 例。与此同时,妇女出现晚期癌症的比率下降了 8%,从每 10 万名妇女 102 例降至 94 例,每 10 万名妇女绝对减少 8 例。假设潜在疾病负担保持不变,在诊断出的 122 例额外早期癌症中,只有 8 例预计会进展为晚期疾病。在排除与激素替代疗法相关的短暂过度发病后,并调整了 40 岁以下妇女乳腺癌发病率的趋势,我们估计在过去 30 年中,美国有 130 万名妇女过度诊断(即在筛查中检测到的肿瘤永远不会导致临床症状)。我们估计,在 2008 年,有超过 70000 名妇女被过度诊断;这占所有诊断出的乳腺癌的 31%。
尽管早期乳腺癌病例数量大幅增加,但筛查性乳房 X 线摄影术仅略微降低了妇女出现晚期癌症的比率。尽管尚不确定哪些妇女受到了影响,但这种不平衡表明存在大量的过度诊断,占所有新诊断乳腺癌的近三分之一,并且筛查对乳腺癌死亡率的影响充其量只是很小。